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Abstract 
Cognitive deficits associated with Alzheimer's disease are known to result from 
decreases in acetylcholine within the cholinergic system ofthe medial septal area, which 
projects to the hippocampus. Recent studies have proposed that increasing levels ofthe 
neurotransmitter norepinephrine may help to decrease the cognitive impairments associated 
with Alzheimer's disease and aging. The present study measured the effects that Guanfacine, 
an alpha-2 noradrenergic agonist, has on memory deficits produced by the acetylcholine 
antagonist, Scopolamine. Memory ability was assessed using an object recognition task and 
a socially transmitted food preference task. Following administration of Scopolamine, 
memory ability was significantly impaired from baseline levels on both memory tasks. Pre­
training injection of Scopolamine followed by post-training injection of Guanfacine resulted 
in memory performance that was equivalent to baseline memory performance on both tasks. 
Guanfacine administration alone did not improve memory performance, but rather had a 
trend toward impairing performance. Results from this study indicate that Guanfacine may be 
effective at improving memory impairments caused by decreased acetylcholine function as 
seen in Alzheimer's disease. 
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The Effects of the Norepinephrine Agonist, Guanfacine, on Scopolamine-Induced 
Memory Impairments in the Rat 
Cognitive deficits seen during aging are known to vary amongst individuals and may 
be ascribed to a continuum, ranging from little or no cognitive deficits to severe memory 
impairments like Alzheimer's disease. Although, some people age with no cognitive deficits 
whatsoever many individuals lose a small part of their cognitive abilities. For example, in 
many elderly persons a marked decrease in reaction time or paired-associate learning, such as 
pairing a name to a face or a phone number to a friend, may be present (Shimamura, Berry, 
Mangels, Rusting, & Jurica, 1995). These deficits are fairly common and are at one end of 
the spectrum. However, these symptoms can get progressively worse as the other end of the 
spectrum is approached and many people also experience these more severe deficits. Aged 
individuals with such deficits may have a hard time remembering simple daily habits, like 
taking medication or keeping up with personal hygiene. Those individuals with the most 
severe cognitive deficits are likely sufferers ofAlzheimer's disease. 
Alzheimer's disease (AD) is a neurodegenerative disease currently affecting nearly 18 
million people worldwide and is projected to affect about 34 million people by the year 2025 
(World Health Organization, 2006). In patients with Alzheimer's disease, a continual 
functional decline is often seen. The decline often begins with the patient's inability to 
remember past events in time. These decreased event remembrances can range from months 
or years ago to events occurring earlier that day. As the disease progresses, cognitive decline 
continues with patients losing the ability to perform many activities of daily living. These 
activities range from basic procedural actions such as eating or bathing to more complex 
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actions such as shopping or using the telephone (Doody, 2003). Extreme Alzheimer's cases 
show patients even losing the ability to remember family members and other loved ones. 
Alzheimer's disease cannot definitively be diagnosed until post-mortem studies can be 
conducted. Patient death usually occurs 8-10 years after symptomatic onset. 
It is obvious that advances in treatment options for age associated cognitive decline 
and AD are needed in order to improve the lack ofmemory function associated with them. 
One potential approach to treatment of Alzheimer's might involve the pharmacological 
norepinephrine agonist, Guanfacine, which has been shown to increase learning and memory 
in both rodent models and human studies (Arnsten, Cai, & Goldmanrakic, 1988; Arnsten & 
Contant, 1992; Jakala, Riekkinen, Sirvio, Koivisto, Kejonen, & Vanhanen, 1999). 
Accordingly, Guanfacine administration might aid in improving long-term memory 
impairments seen in age associated cognitive decline and AD. 
Long-Term Memory 
There are many systems ofmemory that together encompass the concept of long-term 
memory. Recently, Squire (2004) organized long-term memory into a reliable taxonomy, 
which accounts for the relevant brain structures that are associated with different systems of 
memory. This taxonomy breaks long-term memory down into two systems: declarative 
memory and nondeclarative memory. Nondeclarative memory is an unconscious system of 
memory that is responsible for extracting common perceptions from several isolated and 
serial events, allowing one to integrate information from variable contexts. Therefore, 
nondeclarative memory is associated with procedural skills such as riding a bike. It is also 
associated with priming and perceptual learning, simple classical conditioning, and 
nonassociative learning. Declarative memory, which is a conscious system of memory, is 
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broken down into two parts: episodic memory (events) and semantic memory (facts). It 
consists of personal information and is often referred to as "self-knowing" (Tulving, 1985). 
The present study focused on the declarative system of long-term memory. 
Declarative memory. The memory taxonomy proposed by Squire (2004) defines 
declarative memory as recollection-based memory that pertains to facts or personal 
information from single events in time. The declarative memory system is capable of 
processing multiple pieces of information and is often impaired in amnesic patients (Squire, 
1992). Therefore, it is also likely to be impaired in patients with Alzheimer's disease or 
aged-associated cognitive deficits. Declarative memory is often associated with many 
different parts of the brain, but is generally related to the medial temporal lobe, which 
includes the hippocampus, and the diencephalon. The medial temporal lobe contains specific 
parts of the brain, each of which have a role in memory regarding acquisition, integration, 
and recollection. 
Cognitive Decline. As aging occurs, it is normal for certain parts ofmemory to 
decline; however, in AD the decline is extreme. Persons with mild cognitive impairment 
may only lose a few bits of semantic knowledge or a few episodic events. While their ability 
to form new long-term memories may be slightly impaired, they are still able to encode and 
retain most new information into long-term memory. With AD, the impairments seen in 
semantic and episodic memories, as well as ability to encode new information to long-term 
memory, is greatly increased. 
In the beginning stages ofAD, the decline seen is generally quite mild, yet as the 
disease progresses, the decline seen becomes more pronounced (see Illustration 1). 
Nondeclarative memory, specifically procedural memory, usually lasts the longest in AD 
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patients. Declarative memory, however, is generally the first and primary area ofmemory 
affected. Semantic memory declines quite rapidly and patients quickly lose the ability to 
remember specific facts and general knowledge, such as being able to name common 
household objects. Episodic memory also declines quite quickly as patients have a harder 
time remembering past events or pieces of information that are event-based. Short-term 
memory may decline at a slower pace. Some patients still have an intact digit span and can 
hold a normal conversation, remembering questions or information given out previously in 
the conversation. Despite this, ability to encode new long-term memories may still be 
impaired. 
As the effects ofthe disease reach a maximum, memory ability is hardly functional. 
Short-term memory is reduced to almost nothing and patients may not be able to hold a 
conversation that would make sense to a normal person. Patients have lost even more 
semantic knowledge and episodic memories, which include almost all past information tied 
to events. Ability to encode long-term memories is largely gone as well. Many AD patients, 
with extreme symptoms, cannot even recognize names or faces of family members and other 
loved ones. 
Hippocampus 
It is widely accepted from previous studies that the hippocampus (HPC) is 
particularly associated with declarative memory tasks (Astur, Laughlin, Mamelak, Philpott, 
& Sutherland, 2002; Bohbot, Kalina, Stepankova, Petrides, & Nadel, 1998; Smith & Milner, 
1981; Squire, 1992). When intact, the HPC works to provide a means by which new 
information can be encoded from short-term memory to long-term memory. Studies of 
amnesic patients show that severe amnesia is marked by significant damage to the HPC. In 
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general, as damage to the HPC increases so do the cognitive deficits associated with long-
term memory and declarative tasks (Scoville & Milner, 1957). This trend follows the age-
related cognitive decline continuum; patients with little or no damage to the HPC show 
mostly intact long-term memory, however, as seen in Alzheimer's patients, individuals with 
the most damage to the HPC show the most cognitive deficits. 
I 
--~ Alzheimer's Disease ~--.., 
,. 
,, 
Episodic 
(events) 
... 1....__., 
Semantic + 
(facts) 
,, 
+ 
Procedural Skills I 
Nondeclarative Memory 
Declarative Memory 
Short-term Memory 
Illustration 1. The memory systems that Alzheimer's disease affects as it progresses. It is important to 
remember that once AD affects a certain memory system, the deficits seen in that system will continue to 
increase. For example, once AD impairs episodic memory it will continue to decline leading to instances where 
patients may not be able to recognize family members. This flowchart is only a generalization; it is not 
guaranteed that all AD patients will show cognitive impairments in this order. 
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Amnesic patients. Much of the information collected regarding the involvement of 
the HPC in declarative memory tasks in humans has been from patients with amnesia. 
Milner (1962) presented evidence from patient H.M. that the memory is dependent upon the 
medial temporal lobe. The medial temporal lobe, which includes the HPC, was removed 
from patient H.M. bilaterally in order to alleviate epileptic seizures. After removal of the 
medial temporal lobe in H.M., he was found to have severe amnesia and lacked virtually any 
long-term memory ability. Squire (1992) studied the effects of varying amounts of damage 
to the HPC in patients. In patients with more complete damage to the hippocampal 
formation, amnesia can be significant and may span across numerous decades, with sparing 
of very old memories. Hippocampal damage was also shown to affect both factual 
information and autobiographical, event-specific information. 
Functional magnetic resonance imaging. Functional magnetic resonance imaging 
(fMRI) has allowed the role ofthe HPC in declarative memory tasks to be studied more 
extensively (Press, Amaral, & Squire, 1989). The increase in visual acuity allowed from the 
fMRI studies has shown shrinkage in brain areas (fimbria, dentate gyrus, hippocampus 
proper, and subiculum) of the HPC in patients with memory deficits (Squire, 1992). Another 
study showed that the medial temporal lobe was highly activated in persons while listening to 
their previously recorded autobiographical memories (episodic events), suggesting that the 
medial temporal lobe is required for episodic memory (Levine, Turner, Tisserand, Hevenor, 
Graham, & Mcintosh, 2004). These studies have provided even more conclusive evidence 
that the HPC is predominately involved in declarative memory tasks. 
Evidence from rat studies. Memory associated with the rat HPC follows that in 
humans, generally with more hippocampal damage leading to larger and more profound 
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cognitive deficits. The long-term declarative memory impairments similarly implicate the 
role of the HPC (Aggleton, Hunt, & Rawlins, 1986; Opal & Countryman, 2007; Sloan, 
Dobrossy, & Dunnett, 2006; Squire, Clark, West, & Zola, 2001). Studies have shown that, 
similar to human amnesic patients, bilateral lesions to the rat HPC have produced memory 
dysfunction (Barnes, 1988; Sutherland & Rudy, 1989). These studies implicate the extensive 
role of the HPC in memory formation, specifically with declarative tasks. 
Acetylcholine 
Acetylcholine (ACh) exists predominately in the peripheral nervous system and in 
brain tissue. It is synthesized within axon terminals from the precursors choline and acetyl 
coenzyme A (acetyl CoA) via a one-step reaction. Choline acetyltransferase (ChAT), an 
enzyme, aids in the joining of choline and acetyl CoA to form the neurotransmitter ACh. 
After fusing, ACh is released into the synaptic cleft and binds reversibly to receptors on the 
post-synaptic dendritic membrane. Two types of ACh receptors, muscarinic and nicotinic, 
exist in the brain. Excess ACh is then broken down for reuptake by the enzyme 
acetylcholine esterase (AChE). 
While normal aging is associated with decreases of cholinergic neurons in the basal 
forebrain these reductions are not nearly as great when compared to neuronal loss in AD 
patients (Bartus, Dean, Beer, & Lippa, 1982). Multiple studies have shown reduced levels of 
ChAT and AChE in brains of AD patients as compared to a normal-aged sample (Bowen, 
Sims, Benton, Curzon, Davison, Neary, et aI., 1981; Giacobini, 2003; Kuhar, 1976). 
Giacobini (2003) found that AD patients exhibited decreased AChE levels by 60-80%. It is 
logical to hypothesize that decreases in AChE levels is a direct result of decreases in ACh 
neurons because AChE breaks down ACh within the synapse. These reductions indicate that 
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decreased ACh levels might predominately contribute to those AD memory deficits observed 
(Bowen et aI., 1981; Winkler, ThaI, Gage, & Fisher, 1998). AD patients, in particular, have 
shown decreased levels of ChAT in the basal forebrain, which contains the medial septum, a 
main source of ACh to the HPC (Whitehouse, Price, Clark, Coyle, & DeLong, 1981; 
Whitehouse, Price, Struble, Clark, Coyle, & Delong, 1982). 
Memory formation. It is clear that an interaction exists between multiple memory 
systems and the neurotransmitter ACh (Gold, 2004; Kesner, 1998; Whishaw, 1985; White & 
MacDonald, 2002). Whether ACh modulates memory processing or processing modulates 
ACh release has been debated (Gold, 2003). However, as a means of identifying memory 
activation within the hippocampus and other brain regions (e.g., amygdala, striatium, and 
hippocampus), ACh transmission has proven quite useful (Dutar, Bassant, Senut, & Lamour, 
1995; Everitt & Robbins, 1997; Sarter & Bruno, 2000). The present study focused on ACh 
transmission in the hippocampus because the receptors that ACh normally binds to within the 
HPC were effectively blocked through an injection of scopolamine. 
Increased ACh release has been observed in a number ofhippocampal-dependent 
tasks. For example, increased ACh release has been observed in working memory tasks 
(Fadda, Melis, & Stancampiano, 1996). Increases in ACh have also been found in tasks of 
visual discrimination (Yamamuro, Hori, Tanaka, Iwano, & Nomura, 1995). In rats, tasks that 
present a novel stimulus in a novel environment have increased release of ACh (Aloisi, 
Casamenti, Scali, Pepeu, & Carli, 1997; Inglis & Fibiger, 1995). Brain-region specific ACh 
release in the rat has also been observed during performance on a T-maze task (Chang & 
Gold, 2003; McIntyre, Pal, Mamot, & Gold, 2003). These studies provide evidence for the 
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hypothesis that increased ACh levels are correlated to an increase in learning ability. Further 
evidence supports the link between decreased ACh levels and a decrease in memory ability. 
The "cholinergic hypothesis". Impairments in the cholinergic system have been 
hypothesized to account for AD-type memory deficits (Bartus et aI., 1982; Coyle, Price, & 
Delong, 1983). Describing a correlation ofthis magnitude must consider three criteria 
elaborated by Bartus et aI. (1982): 
(i) specific dysfunctions in cholinergic markers should be found in the brains of 
subjects suffering from age-related memory loss (ii) artificial disruption of central 
cholinergic function in young subjects should induce behavioral impairments that 
mimic the cognitive loss found naturally in aged subjects and (iii) appropriately 
enhancing central cholinergic activity in aged subjects should significantly reduce 
age-related cognitive deficits. (p. 408) 
Enhancement ofthe cholinergic system. Enhancement of the cholinergic system has 
been shown to decrease memory deficits (Suzuki, Yamatoya, Sakai, Kataoka, Furushiro, & 
Kudo, 2001). One such method involves the use of ACh precursors. Upon injection into the 
brain, precursors become converted into choline, thus allowing for increased synthesis of 
ACh from choline and acetate. One such precursor, lecithin, is correlated to marked 
increases in perfotmance on a Morris water maze task after administered orally to rats 
exhibiting AD-type deficits (Suzuki et aI., 2001). In addition, rats displaying AD-type 
memory deficits following Scopolamine administration exhibited decreases in impairment 
after the delivery of lecithin (Furushiro, Suzuki, Shishido, Sakai, Yamatoya, & Kudo, 1997). 
Similarly, rats subcutaneously administered the precursor, choline chloride, displayed 
increases in performance on the same Morris water maze task (Tees & Mohammadi, 1999). 
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While ACh precursors have produced evidence for decreasing memory deficits, beneficial 
effects are extremely limited and lack effectiveness (Kumar, Durai, & lobe, 1998). 
Recently, assessing such increases in ACh in live and awake animals has been made 
possible due to novel advances in technology (e.g., fMRI, mircodialysis, HPLC). For 
example, a precursor to ACh synthesis, choline has been shown to increase in uptake within 
ACh neurons throughout memory tasks (Messier, Durkin, Mrabet, & Destrade, 1990). 
Additionally, glucose injection into the HPC increases ACh release during memory­
dependent training tasks in the rat (Ragozzino, Wenk, & Gold, 1994; Ragozzino, Unick, & 
Gold, 1996; Ragozzino, Pal, Unick, Stefani, & Gold, 1998). 
Impairment ofthe cholinergic system. There is substantial support for the hypothesis 
that a decrease in ACh is associated with decreased memory performance. For example, 
morphine injection into the intraseptal pathway in the HPC decreases ACh release and 
memory processing (Ragozzino & Gold, 1995). Galanin, a neuropeptide, has been shown to 
decrease both ACh release and learning on spatial tasks in the rat (Ogren, Kehr, & Schott, 
1996). 
Deliberate impairments made to the cholinergic system in rat subjects have produced 
memory deficits similar to those seen in AD subjects (Carli, Luschi, & Samanin, 1997; 
Decker, Radek, Majchrzak, & Anderson, 1992; Farr, Flood, & Morley, 2000; Gold, 2003; 
Hagan, Salamone, Simpson, Iversen, & Morris, 1988; Lilliquist, Burkhalter, Lobaugh, & 
Amsel, 1993; Ohno, Yamamoto, & Watanabe, 1994; Wallenstein & Vago, 2001; Walsh, 
Herzog, Gandhi, Stackman, & Wiley, 1996). Much of the work dealing with cholinergic 
impairment within the HPC has been limited to administration of cholinergic antagonists, 
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such as Scopolamine, or chemica11esions to the medial septum, a brain region where ACh 
neurons originate. 
The septal-hippocampal (SH) projection of cholinergic neurons in the medial septum 
and vertical limb of the diagonal band (MS/VDB) are believed to provide the main source of 
ACh to the hippocampus (Dutar et aI., 1995; Segal & Auerbach, 1997) (see Figure 3). The 
SH pathway originates within the basal forebrain, particularly the medial septum. The 
medial septum is divided into the medial septal nucleus and nucleus of the vertical and 
horizonta11imbs of the diagonal band ofbroca (McKinney, Coyle, & Hendreen, 1983; Dutar 
etaI.,1995). 
Decreases in ACh resulting from lesions to the MSNDB have been associated with 
decreases in hippocampal-dependent memory ability (Bartus et aI., 1982; Opal & 
Countryman,2007). For example, decreases in working memory have been found following 
lesion to the MS/VDB (Decker et aI., 1992; Walsh et aI., 1996). Also, many studies have 
shown that lesions to the rat MS not only result in decreased levels ofACh, but also 
decreased levels of AChE and ChAT in the HPC (Lewis, Shute, & Silver, 1967; Oderfe1d­
Nowak, Nariewicz, Bia10was, Dabrowska, Wieraszko, & Gradkowska, 1974; Potemska, 
Gradkowska, & Oderfe1d-Nowak, 1975). This provides support for the link between ACh 
levels and subsequent levels ofAChE and ChAT. 
Furthermore, a memory-based place navigation task has displayed marked 
impairment following lesion to the MSNDB in the rat (Hagan et aI., 1988). Similarly, 
spatial memory performance has decreased in rats following chemica11esion to the 
intrasepta1 pathway in the MS/VDB (Janis, G1asier, Fulop, & Stein, 1998; Nilsson, Leanza, 
Rosenb1ad, Lappi, Wiley, & Bjok1und, 1992). Memory deficits resulting from lesions to the 
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MS/VDB produce strikingly similar learning and memory impairments as seen in damage to 
the HPC (Hagan et aI., 1988; Decker et aI., 1992; Janis et aI., 1998). It is reasonable to 
conclude that learning and memory is most likely modulated by the interdependent 
functioning of ACh within both brain regions. 
Scopolamine. Scopolamine amnesia has often been proposed as a pharmacological 
model for human dementia and for AD (Bartus, Bean, Pontecorvo, & Flicker, 1985 as cited 
in Bertaina-Anglade, Enjuanes, Morillon, & Drieu la Rochelle, 2006). Scopolamine works 
by blocking ACh receptors in the brain. Since the HPC is a brain structure central to learning 
and memory, which contains a large concentration ofACh receptors, it makes sense that 
scopolamine would induce large memory impairments. These impairments are likely due to 
an inability to encode new information and store it as a long-term memory (Rogers & 
Kesner, 2003). Scopolamine is of particular interest for the present study, as it will serve to 
impair ACh functioning in the HPC and, therefore, also impair memory ability. 
The muscarinic receptor antagonist, Scopolamine, has been shown to effectively and 
temporarily impair memory ability in humans and rats (Bertaina-Anglade et aI., 2006; Boix­
Trelis, Vale-Martinez, Guillazo-Blanch, & Marti-Nicolovius, 2006; Fujiwara, Ohgami, 
Inada, & Wasaki, 1996; Rammsayer, Rodewald, & Groh, 1999; Rogers & Kesner, 2003; 
Winters, Saksida, & Bussey, 2006). Two specific tasks, which have been impaired by 
Scopolamine, the social transmission of food preference task and the object recognition task 
are of particular interest, as these tasks will be utilized as measures ofmemory ability in the 
present study. 
Acetylcholine esterase inhibitors. Acetylcholine esterase inhibitors (AChE-Is) have 
been the most promising pharmacological treatment of memory impairments seen in AD 
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patients. AchE-Is work to increase the availability of ACh in the brain by preventing the 
hydrolysis of ACh from the enzyme acetylcholine esterase (Prickaerts, Sik, van der Staay, de 
Vente, & Blokland, 2005; Rogers, 1998). Since ACh receptor activity in the HPC and MS 
has been shown to increase memory performance, AchE-Is have been utilized in the AD 
population to aid in delaying memory impairments (Delagarza, 2003; Kumar et aI., 1998; 
Rogers,1998). Currently, there are four AchE-Is that have been approved by the Food and 
Drug Administration for use in AD: Tacrine (Cognex), Rivastigamine (Excelon), Donepezil 
(Aricept), and Galantamine (Reminyl). 
Despite the memory improvements seen with the use of AchE-Is, many problems 
with this pharmacological treatment of AD exist. First, the inhibition ofACh hydrolysis 
causes serious side effects in AD patients. Side effects ofAchE-Is include: nausea, anorexia, 
aggression, liver toxicity, and cardiovascular irregularities (Lazartigues, Freslon, Telliogu, 
Brefel-Courbon, Pelat, Tran, Montastruc, & Rascol, 1998). Second, AchE-Is have exhibited 
low levels of efficacy in AD patients because these agents only moderately delay memory 
impairment (Doody, 2003). One study indicates that only 20% ofAD patients will 
experience a one-year delay in full cognitive impairments (Tariot, Solomon, Morris, 
Kershaw, Lilienfeld, & Ding, 2000). Finally, AchE-Is do not cure or avert the onset of AD. 
No single treatment for AD is capable of obtaining such results. As AD progresses and 
levels ofACh continue to decrease, cholinergic AchE-I therapies decrease drastically in 
effectiveness (Lazartigues et aI., 1998; Mann, Yates, & Hawkes, 1982). Additionally, 
pharmacological treatment of AD symptoms with AchE-Is only remains effect for one to two 
years at most. The inhibition of AChE works while there is ACh still present in the brain but 
once ACh is nearly depleted, as AD progresses, the inhibition ofAChE has no effect. 
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Norepinephrine 
One reason cholinergic treatments are not more effective in ameliorating deficits in 
AD patients is that AD is not solely a cholinergic insufficiency. AD is a very complex illness 
and is likely to induce impairments in multiple neurotransmitter pathways (0'Amato, Zweig, 
Whitehouse, Wenk, Singer, & Mayeux, 1987; Herrmann, Lanctot, & Khan, 2004). 
The norepinephrine (NE) system contains two projection orientations: (1) the ventral 
noradrenergic bundle, forming a main part of the lateral tegmental system and (2) the 
ascending dorsal noradrenergic bundle of the locus coeruleus system. The dorsal bundle is of 
particular interest in the present manipulation because it projects directly into the 
hippocampus. The locus coeruleus (LC) is the predominant brain structure that provides the 
main source of NE to the HPC. In fact, fibers projecting to the HPC from the LC pass 
through the MS, possibly implicating an interaction between ACh and NE (Loy, Milner, & 
Moore, 1980). 
Locus coeruleus. The LC is the largest noradrenergic nucleus in the human and rat 
brain, containing approximately 15,000 NE neurons per hemisphere in humans and 1,600 
neurons per hemisphere in rats (Coull, 1994; Foote, Bloom, & Aston-Jones, 1983; Rogawski, 
1985). It innervates roughly every component of the telencephalon and the diencephalon, the 
most notable ofwhich is the HPC. The LC contains alpha (a) and beta (~) receptor types. 
The ~-receptor type is further divided into ~l, ~2, and ~3-receptor subtypes. ~-receptors have 
been isolated in the heart, spleen, bladder, and other major organs. The a-receptor type is 
divided into ala, alb, aId, a2a, a2b, and a2e-receptor subtypes. Areas of high-affinity a2­
receptor binding include the dentate gyrus of the hippocampus and the substantia nigra pars 
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reticulata (Herrmann et aI., 2004). In general, a-receptors are found in the central nervous 
system and ~-receptors are found in the peripheral nervous system. 
Norepinephrine and Alzheimer's disease. While degradation of the ACh pathway has 
been studied extensively in AD patients, the NE neurotransmitter pathway has been 
investigated less thoroughly. However, several studies indicate that the NE neurotransmitter 
pathway may be involved in AD as decreased levels ofNE have been noted in AD patients 
(Bondareff, Mountjoy, & Roth, 1981; Mann, Lincoln, Yates, Stamp, & Toper, 1980; Mann et 
aI, 1982). Therefore, a shortage ofNE from the LC might substantially contribute to the lack 
of memory function associated with AD (Bondareff et aI., 1981; Bondareff, Mountjoy, & 
Roth, 1982; Chanpalay, 1991). These studies provide evidence for the interaction of the ACh 
and NE neurotransmitter systems in AD patients and memory ability in general. 
Marked decreases of noradrenergic neurons in the LC have been well established in 
patients with age associated cognitive impairments, specifically in AD (Hermann et aI., 2004; 
Hoogendijk, Feenstra, Botterblom, Gilhuis, Sommer, & Kamphorst, et aI., 1999; Mann, 
1983; Szot, White, Greenup, Leverenz, Peskind, & Raskind, 2005). Furthermore, the biggest 
decrease in NE neurons has been seen in the center of the LC (Marcyniuk, Mann, & Yates, 
1986). This evidence is significant because the central part of the Leis thought to project to 
the HPC. 
Norepinephrine and acetylcholine. The evidence above shows that NE and ACh 
neurotransmitter systems interact in the modulation ofmemory formation within the HPC. 
Decker & McGaugh (1991) have presented anatomical details of such an interaction (see 
Illustration 2). Results have shown that blockade of either system lead to memory 
impairments (Sirvio & MacDonald, 1999). Many studies have also shown that ACh and NE 
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modulate each other's release within the HPC (Azam & McIntosh, 2006; Moroni, Tanganelli, 
Antonelli, Carla, Bianchi, & Beani, 1983). For example, stimulation ofNE receptors in the 
MS produce increases ofACh in the HPC (Robinson, Cheney, & Costa, 1978). This 
interaction is especially helpful in explaining the role ofNE in the AD population. 
NE Locus 
Coeruleus 
NE 
,,. 
Medial 
Septum 
NE 
Amygdala Cortex 
ACh 
-
l' 
Hippocampus 
ACh 
-
Ir 
NBM 
ACh 
Illustration 2. Hypothetical model of sites at which cholinergic and noradrenergic interactions might occur. 
Darker lines indicate norepinephrine projections while thin lines indicate acetylcholine projections. NBM refers 
to the nucleus basilis magnocellularis. 
One study by Kruglikov (1982) provided further evidence that memory is modulated 
by NE and ACh collectively. Normal animals were given scopolamine and exhibited 
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decreases in memory on an avoidance task. Next, rats that had been administered the 
scopolamine were given a LC lesion. The combination ofthe LC lesion and scopolamine 
produced much larger impairments. In conclusion, pharmacological agents merely targeting 
the ACh system may be one reason cholinergic therapies within the AD populace are 
ineffective. 
Norepinephrine agonists. Considering the nature ofleaming and memory tasks, in 
which NE potentially interacts with the cholinergic system, NE agonists might be useful in 
reducing memory deficits observed within Alzheimer's patients. Several studies have 
indicated that alpha-2 receptor subtype adrenergic agonists improve memory on a variety of 
tasks (Amsten et aI., 1988; Amsten & Goldman-Rakic, 1990; Amsten & Leslie, 1991; 
Amsten & Contant, 1992; Amsten & Cai, 1993; Jakala, et aI., 1999; Rama, Linnankoski, 
Tanila, Pertovaara, & Carlson, 1996; Sirvio, Riekkinen, Vajanto, Koivisto, & Reikkinen, 
1991). In the present experiment, one such agonist, Guanfacine, was administered to rats in 
an attempt to improve memory impairments induced by Scopolamine. 
Guanfacine has been shown to increase memory performance in numerous animal 
and human studies. For example, Guanfacine has been shown to improve delayed response 
performance in aged monkeys (Rama et aI., 1996). In addition, low doses ofGuanfacine 
have improved performance in aged rats on a spatial navigation task (Sirvio et aI., 1991). 
Furthermore, Guanfacine has improved memory in aged monkeys on tasks involving the 
utilization of working memory (Amsten et aI., 1988; Amsten & Cai, 1993). Guanfacine has 
shown similar effective results in humans, improving performance on working memory tasks 
(Jakala et aI., 1999). 
Memory Deficits and Guanfacine 25 
The NE agonist, Guanfacine, is an exciting, novel phannacological agent that may be 
useful in the treatment of AD-type memory deficits. Studies involving the administration of 
Guanfacine after Scopolamine induced memory impairments on a socially transmitted food 
preference task and an object recognition task are nonexistent. The present study allowed for 
new conclusions to be made on the interaction between the NE and ACh transmitter 
pathways in memory and AD. 
Current Study 
Object recognition task. The object recognition task (ORT) was also used as a 
quantification of memory performance in the current study. The object discrimination task 
has been utilized as a marker for memory performance in numerous studies (Bertaina­
Anglade et aI., 2006; Bowman, Maclusky, Diaz, Zrull, & Luine, 2006; Silvers, Harrod, 
Mactutus, & Booze, 2007; Tzavara, Bymaster, Overshiner, Davis, Perry, Wolff et aI., 2005). 
The ORT has often been a reliable and popular method for its ability to test memory 
performance without putting undue stress on an animal (Silvers et aI., 2007). Furthermore, 
the task places few requirements on the animal and allows the experimenter to directly 
observe and record behavior. Also, scopolamine has been shown to impair long-term 
memory formation on the object recognition task (Bertaina-Anglade et aI., 2006). Overall, it 
is a task that is eaSy to train and test on in one day. In the current study, it also served as a 
confirmation for memory abilities of rats on the STFP task. Explanation of the ORT that was 
used in this study can be found under the methods section. 
Social transmission offood preference task. In order to quantify memory 
performance, a socially transmitted food preference task (STFP) was utilized. The STFP task 
is a nonspatial and spontaneous learning task. There are several benefits to using the STFP 
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task in order to measure memory formation within the current study. First, all food 
preferences are acquired in one training period with the demonstrated food, allowing for time 
points to be defined for acquisition and recall of the food preference. Second, food 
preferences, when transmitted socially, persist for several weeks, which will allow for 
sufficient testing time periods. Third, rats acquire the food preference through undemanding 
circumstances, which do not encompass spatial abilities, visual acuity, or exhausting 
locomotor activity (Countryman & Gold, 2007). 
Existing literature indicates that observer rats exhibit a food preference after being 
exposed to a demonstrator rat that has recently consumed a flavored rat chow (Galef & 
Whiskin, 2003; Vale-Martinez, Baxter, & Eichenbaum, 2002). For example, an observer rat 
having been presented cocoa flavored chow via a demonstrator rat will exhibit preference to 
this flavored food for periods extending over one month (Clark, Broadbent, Zola, & Squire, 
2002). This suggests that the rat has formed a declarative memory for cocoa-flavored chow. 
In relation to the present study, administration of scopolamine prior to training on STFP task 
has been shown to impair long-term memory formation (Boix-Trelis et aI., 2006). 
Studies have shown increases in CREB phosphorylation and c-Fos expression in the 
HPC during a STFP task (Countryman & Gold, 2007; Countryman, Orlowski, Brightwell, 
Oskowitz, & Colombo, 2005). It is also known that CREB phosphorylation and c-Fos 
expression are both paramount in long-term memory formation (Brightwell, Smith, 
Countryman, Neve, & Colombo, 2005; Countryman, Kaban, & Colombo, 2005). 
Consequently, increases in either CREB or c-Fos can be used as a marker for long-term 
memory processing. This is very significant evidence indicating that the STFP task can be 
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used to quantify "declarative-like" memory fonnation. Explanation of the STFP task that 
was used in this study can be found under the methods section. 
Summary and implications. After a review of the literature it is clear that the 
hippocampus is extensively involved in declarative memory tasks. The decrease in 
neurotransmitter acetylcholine has been shown to impair memory fonnation within the 
hippocampus. Reductions in acetylcholine levels within the hippocampus and medial septum 
have been observed in Alzheimer's disease patients. Scopolamine is an effective method by 
which to block acetylcholine receptors in the hippocampus and impair memory perfonnance. 
Reductions in levels of the norepinephrine neurons in the center of the locus coeruleus have 
been associated with Alzheimer's disease. Numerous studies have, therefore, implicated the 
possible interaction of the acetylcholine and norepinephrine neurotransmitter systems in age 
associated cognitive impainnents and Alzheimer's disease. Norepinephrine agonists, 
particularly the alpha-2 noradrenergic agonists have shown to increase perfonnance on a 
number of memory-related tasks in aged animals and humans. However, few studies have 
examined the effects ofnorepinephrine agonists on Alzheimer's-like memory impainnents. 
Furthennore, no studies have investigated the effect of Guanfacine on long-tenn declarative 
memory after induced memory impainnents by the administration of Scopolamine. 
Therefore, the present study measured the effects that two different doses of Guanfacine, a 
high dose and a low dose, had on memory perfonnance in an object recognition task and the 
effects that a low dose of Guanfacine had on memory perfonnance in a socially transmitted 
food preference task following administration of Scopolamine to the rat. 
Hypotheses. Numerous hypotheses exist for the current study (see Table 1). The 
main hypotheses for the present study include implications of Scopolamine administration on 
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memory ability compared to saline treated rats. The implications of Guanfacine, a high dose 
and low dose, on memory ability in both scopolamine and saline treated rats are also listed. 
Overall, it is predicted that Scopolamine will effectively impair memory ability on both the 
STFP task and the ORT and that Guanfacine will reverse these memory impairments. Also, 
it is hypothesized that rats administered saline and treated with Guanfacine will have higher 
memory ability than at baseline. 
Table 1 
Summary of hypotheses 
1.	 Rats administered Scopolamine prior to training on the STFP task and the ORT and 
treated with saline after training will show significant memory impairments during 
recall. 
2.	 Rats administered Scopolamine prior to training on the STFP task and the ORT and 
treated with a low dose of Guanfacine after training will perform better during recall 
than rats administered Scopolamine and treated with saline. 
3.	 Rats administered Scopolamine prior to training on the STFP task and the ORT and 
treated with a high dose of Guanfacine after training will perform better during recall 
than both rats administered Scopolamine and treated with a low dose of Guanfacine 
and rats administered Scopolamine and treated with saline. 
4.	 Rats administered saline prior to training on the STFP task and ORT will perform 
better than baseline during recall when treated with Guanfacine after training on the 
STFP task and ORT. 
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Methods 
Subjects 
Subjects for this study were twenty-four Long-Evans male rats, purchased from 
Harlan (Indianapolis, IN). During the course ofthe experiment, twelve rats served as 
demonstrator rats (d-rats) and twelve rats served as subject rats (s-rats/experimental rats). 
Rats were maintained on a 12 hour light-dark schedule and in a humidity and temperature­
controlled environment. Throughout this study, rats were pair-housed, based on d-rat or s-rat 
status, in 42 x 24 x 27 cm plastic bottom cages. 
Food and water were available ad libitum except during the five days prior to each 
socially transmitted food preference training session. During this time, rats were placed on a 
22-hour food deprivation schedule with ad libitum water. All rats were housed and handled 
according to the Guidefor the Care and Use ofLaboratory Animals (National Academy 
Press, Washington, D.C., 1996) and Illinois Wesleyan University IACUC. Following arrival 
in the lab and prior to any behavioral testing, all rats were allowed to habituate to 
surroundings for one week, throughout which they were handled for five minutes a day. 
Object recognition task 
An object recognition task was first utilized following similar procedures as Tzavara 
et al. (2006). S-rats were trained on the task and were then tested on the task following a 3­
hour delay. Each rat was placed in the center of a 64 x 33 x 41 cm wooden observation box 
containing two identical objects (noted as object A) at either end of the box. Each s-rat was 
allowed to explore the objects for 3 minutes and the time spent interacting with each object, 
designated right or left, was recorded. For this task, interacting was defined as sniffing at, 
whisking at, gnawing at, or looking at the object from no more than 2 cm away. Behavior 
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not oriented to the objects (accidental sitting, standing on the object, or touching the object 
while passing by) was not quantified. Following the 3-hour delay period, s-rats were 
returned to the box one by one. Each rat was placed in the same center location of the box as 
in the training session. For the testing trial, the box contained a familiar object (object A) 
and a novel object (object B). To account for right or left side biases, object A and object B 
were counterbalanced and randomly switched to the opposite side of the box between every 
few test subjects. The amount oftime spent interacting with each object, either familiar or 
novel, was recorded for three minutes. Different combinations of objects (wooden blocks, 
Lego blocks, cups, small tin flower pots with marbles, etc.) were used for each 
training/testing session (see Figure 3). 
Social transmission offood preference task 
The social transmission of food preference (STFP) task followed similar procedures 
as those utilized by Countryman, Orlowski, et aI., (2005). D-rats and s-rats were placed on 
23-hour food deprivation and were only allowed to eat in one-hour blocks five days prior to 
training on the task. Water was continually available ad libitum throughout all food 
deprivation and testing procedures. On the day prior to training, each d-rat and each s-rat 
were situated in opposite sides of an approximately 42 x 24 x 27 cm plastic bottom 
interaction cage. The cage was equipped with corncob bedding and a wire-mesh screen 
dividing the apparatus into half. Each d-rat was housed on one side of the screen and each s­
rat was housed on the other side. 
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Fig 3. Pairs ofobjects used for object recognition task. 
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During training on the STFP task, d-rats were taken from the interaction apparatus 
and placed into an isolated room. In this location, d-rats were allowed to eat for 30 minutes 
from approximately 10 g of flavored rat chow. Ground rat chow was mixed with specific 
flavors in accordance with a food pair chart (see Table 2). D-rats were permitted to drink 
water whenever food was present. After 30 minutes passed, d-rats were returned to their 
individual interaction cage and allowed to interact for 30 minutes with s-rats through the 
wire-mesh divider in a training/learning session. Immediately following the 30-minute 
interaction period, d-rats and s-rats were returned to home cages and fed unflavored rat chow. 
After 5 days in home cages, s-rats were taken to a novel room and tested for food preference. 
Following food preference testing, d and s-rats were returned to normal food and water 
available ad libitum. 
The testing portion of the food preference task took place in a 42 x 24 x 27 cm plastic 
bottom cage. Two food cups were available, one on either side of the cage. The cups 
contained approximately 109 each of separate flavored rat chow (see Table 2). S-rats were 
placed in the middle of the cage so that they were equidistant from each food cup. Each s-rat 
was permitted to eat from the food cups for one hour with water available for the entire hour. 
Following the one-hour feeding period, the amount of remaining foodfor each flavor was 
weighed. The amount of each flavored food consumed during the food preference task was 
used to calculate the percentage of demonstrated food consumed according to the following 
criteria: (l) (Demonstrated food offered - Demonstrated food remaining) + (Novel Food 
offered - Novel food remaining) = Total food consumed; (2) [Demonstrated food consumed 
(g)/Total food consumed (g)] x 100 = Percentage ofdemonstrated food consumed. 
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The STFP task was administered four times in the current study. For each of these 
administrations, a different food pairing was used (see Table 2). Each food pair served to 
train and test all twelve s-rats. The first six s-rats tested will be demonstrated one of the 
flavored rat chows from a food pair and the next six s-rats will be demonstrated the opposite 
flavored rat chow in the food pair. 
FOOD A FOODB 
PAIR 1 Marjoram (1 %) Coriander (1 %) 
PAIR 2 Nutmeg (0.8%) Ginger (1 %) 
PAIR 3 Oregano (2%) Cumin (1%) 
PAIR 4 Thyme (1%) Turmeric (1 %) 
Table 2. Food pairs. This is a representation of food pairs used throughout the STFP task. Either FOOD A or 
FOOD B in a certain food pair was demonstrated to d-rats. S-rats were then presented both FOOD A and 
FOOD B during testing of preference. Demonstrated food was counterbalanced within food pair groups in 
order to ensure that novel food is presented during each STFP trial period. 
Procedural Timeline 
A procedural timeline that encompassed five experiments (treatment conditions) for 
the ORT (see Table 3) and four experiments (treatment conditions) for the STFP (see Table 
4) assessed memory ability for all s-rats. First, baseline measures of s-rats were collected. 
Afterwards, three experiments effectively investigated the effects of Scopolamine and 
Guanfacine administration on the memory ability of s-rats on the ORT and two experiments 
investigated the effects for the STFP task. S-rats were divided into two groups for each 
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experiment. Both groups of s-rats received the same doses of Scopolamine and Guanfacine, 
both a high and low dose for the ORT and a low dose for the STFP task, but during different 
experiments. This served as an effective counterbalancing method. The final experiment 
(treatment condition) for the ORT and STFP task investigated the effects of Guanfacine 
alone on memory performance by utilizing saline instead of Scopolamine. Saline injected 
rats received the overall most effective dose of Guanfacine, either high or low, administered 
in the previous experiments for the ORT and received the low dose of Guanfacine in the 
STFP task since the high dose was not tested. 
A few implications of Scopolamine and Guanfacine should be discussed further. The 
dose of Scopolamine and saline given in all experiments were 1 mg/kg. The high and low 
doses of Guanfacine were 0.375 mg/kg and 0.125 mg/kg, respectively. All drugs were 
administered to s-rats via injection into the intraperitoneal cavity. Since Scopolamine and 
Guanfacine act on separate neurotransmitter pathways, it is thought that no interaction effects 
occurred. Also, the half-lives of Scopolamine and Guanfacine are short enough that no 
carryover effects are thought to have occurred between experiments. The details of the 
experiments are discussed below. 
In each of the experimental treatment conditions that require pharmacological agents 
(therefore, excluding baseline conditions) Scopolamine (or saline in the final experiments) 
was administered to s-rats five minutes prior to training on the ORT and the STFP task. 
Training for the ORT refers to the placement of rats in the box for exposure to the "familiar" 
objects. The STFP task training refers to the 3D-minute interaction period between d- rats 
and s-rats. Guanfacine, either high or low dose, (or saline) was administered to s-rats 30 
minutes after training in both the ORT and STFP task. 
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Exp.1 Exp.2 Exp.3 Exp.4 Exp.S 
Group 1 Baseline Scopolamine 
+ 
Saline 
Scopolamine 
+ 
Guanfacine 
(Low) 
Scopolamine 
+ 
Guanfacine 
(High) 
Saline 
+ 
Guanfacine 
(High) 
Group 2 Baseline Scopolamine 
+ 
Guanfacine 
(Low) 
Scopolamine 
+ 
Guanfacine 
(High) 
Scopolamine 
+ 
Saline 
Saline 
+ 
Guanfacine 
(High) 
Table 3. Procedural Timeline. Representation of administered drugs for each group of s-rats during each 
experimental condition of the ORT. Each experiment includes training (first listed drug) and testing (second 
listed drug) on the task. High/Low denotes whether Guanfacine administered is a high dose or a low dose. 
Exp.1 Exp.2 Exp.3 Exp.4 
Group 1 Baseline Scopolamine 
+ 
Saline 
Scopolamine 
+ 
Guanfacine 
(Low) 
Saline 
+ 
Guanfacine 
(Low) 
Group 2 Baseline Scopolamine 
+ 
Guanfacine 
(Low) 
Scopolamine 
+ 
Saline 
Saline 
+ 
Guanfacine 
(Low) 
Table 4. Procedural Timeline. Representation of administered drugs for each group of s-rats during each 
experiment of the STFP task. Each experiment includes training (first listed drug) and testing (second listed 
drug) on the STFP. 
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Results 
Object Recognition Task 
A repeated measures (rm) ANOVA was used to determine the amount of time rats 
spent with the novel object under each of the drug conditions (baseline, Scopolamine + 
saline, Scopolamine + low dose Guanfacine, Scopolamine + high-dose Guanfacine, and 
Saline + high dose Guanfacine). The rm ANOVA revealed that the time rats spent with the 
novel object differed significantly across drug treatments, F (4,44) = 3.3060,p < .05. 
Fisher's LSD was performed to determine where the differences occurred. Results showed 
that Scopolamine + saline caused memory impairment as compared to baseline. Also, when 
Guanfacine (high or low dose) was administered in conjunction with Scopolamine, memory 
impairments were reversed in comparison to treatment with Scopolamine alone, all 
p values < .05 (see Figure 1). The saline + Guanfacine treatment condition did not 
significantly differ from any of the other treatment conditions, all p values> .05 but indicated 
a moderate decrease in memory performance from baseline, Scopolamine + low dose 
Guanfacine, Scopolamine + high dose Guanfacine conditions, and better memory 
performance than the Scopolamine + saline condition (see Figure 4). T-tests for independent 
samples were conducted in order to compare the results of the object recognition task, across 
conditions, to the 50% chance level. Baseline measures as well as Scopolamine + low dose 
Guanfacine and Scopolamine + high dose Guanfacine conditions were shown to differ 
significantly from chance levels, t (11) = -7.254, t (11) = -3.064, t (11) = -2.254, all 
p values < .05. Scopolamine + saline and Saline + high dose Guanfacine conditions were not 
shown to differ significantly from chance levels. 
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Figure 1. Object Recognition Task Results. Dotted line represents chance levels and asterisks 
represent significance. 
Social Transmission ofFood Preference Task 
A repeated measures ANOVA was used to determine the percentage of demonstrated 
food consumed by rats under each drug treatment condition (baseline,' Scopolamine + saline, 
Scopolamine + low dose Guanfacine, and Saline + low dose Guanfacine). The rm ANOVA 
revealed that the percentage of demonstrated food consumed by rats significantly differed 
across treatment conditions, F (3,33) = 8.8616,p < .05. Fisher's LSD was performed to 
determine where the differences occurred. Results of this analysis showed that Scopolamine 
+ saline and saline + low dose Guanfacine conditions caused memory impairments compared 
to baseline and Scopolamine + low dose Guanfacine conditions, all p values < .05 (see Figure 
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2). Independent samples t-tests were conducted in order to compare the results ofthe social 
transmission of food preference task, across conditions, to chance levels. Baseline and 
Scopolamine + low dose Guanfacine conditions were shown to differ significantly from 
chance, t (11) = -12.95 and t (11) = -2.83, bothp values < .05. The Scopolamine + saline and 
saline + low dose Guanfacine conditions were not shown to differ significantly from chance 
levels. 
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Figure 5. Social Transmission of Food Preference Task Results. Dotted line represents chance levels 
and asterisks represent significance. 
A repeated measures ANOYA was conducted to determine the total amount of food 
eaten by rats across treatment conditions (baseline, Scopolamine + saline, Scopolamine + 
low dose Guanfacine, and saline + low dose Guanfacine) during food preference testing. A 
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significant effect was found, where the total amount of food eaten by rats differed 
significantly across conditions, F (3,33) = 3.4679,p < .05. Fisher's LSD was conducted to 
determine the differences occurred. Results showed that significantly lower amounts of total 
food were consumed by rats under the Scopolamine + saline, Scopolamine + low dose 
Guanfacine, and saline + low dose Guanfacine conditions compared to the baseline 
condition, all p values < .05 (see Figure 3). 
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Figure 3. Total Amount of Food Consumed. Asterisks represent significance. 
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Discussion 
Administration of the cholinergic antagonist, Scopolamine, was utilized in the present 
study in order to investigate changes on two hippocampal-dependent memory tasks: the 
object recognition task and the social transmission of food preference task. Therefore, 
reductions in performance on both memory tasks were expected following injection of 
Scopolamine prior to training. Following injection of Scopolamine and training on each of 
the tasks, injection of the norepinephrine agonist, Guanfacine, was employed in order to 
examine any increased memory performance from memory-impaired levels. Guanfacine 
administration was expected to increase memory performance by compensating for decreased 
acetylcholine levels within the hippocampus. 
Summary ofResults 
Object recognition task. Rats injected with Scopolamine prior to training on the ORT 
and treated with saline after training on the tasks showed impaired memory performance 
compared to baseline conditions. In the ORT, quantification of memory ability showed that 
rats treated with Scopolamine and saline explored a novel object 48% of the time compared 
to baseline levels when rats spent 63% of the time exploring the novel object. This indicates 
that rats performed no better than chance. Rats injected with Scopolamine prior to training 
and treated with a low dose of Guanfacine after training showed an improvement in memory 
ability during testing. Rats in this condition spent 58% of the time with a novel object 
compared to the 48% observed under the Scopolamine and saline condition. When rats were 
treated with a high dose of Guanfacine instead of a low dose, memory ability was still 
significantly better compared to the Scopolamine and saline condition. A high dose of 
Guanfacine resulted in slightly better performance on the ORT (61 % compared to 58%) but 
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this improvement was not significantly different than the Scopolamine + low dose 
Guanfacine condition. Under the final condition, which investigated the effects of a high 
dose of Guanfacine alone, no significant findings were found. Despite the lack of 
significance, rats performed at a lower level during testing than in baseline conditions as well 
as the other two Guanfacine conditions but still performed better than in the Scopolamine and 
saline condition. 
Social transmission offood preference task. In the STFP task, rats injected with 
Scopolamine prior to training and saline after training showed impaired memory 
performance compared to baseline conditions. Quantification of memory performance 
showed that of the total amount of food rats in the Scopolamine and saline condition 
consumed, only 42% was the demonstrated food compared to the 80% that was demonstrated 
food in baseline conditions. This indicates that rats performed no better than chance. When 
rats treated with Scopolamine prior to training were treated with a low dose of Guanfacine 
after training memory performance was observed to be better than in the Scopolamine and 
saline condition. Rats in this condition consumed 69% of the demonstrated food compared 
to the 42% consumed in the Scopolamine and saline condition. However, performance was 
not as high as in baseline conditions. In the final condition, in which saline was administered 
prior to training and a low dose of Guanfacine was administered after training, no significant 
effects were found. It should be noted that despite lack of significance, rats did perform at a 
lower level than in baseline and Scopolamine + Guanfacine conditions. This is a point that 
will later be discussed further. Additionally, during the STFP task it was found that rats 
consumed significantly less amounts of total food under all drug treatment conditions 
compared to baseline conditions. 
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Effects ofScopolamine on Memory 
Object recognition task. In line with previous research, it was expected that 
Scopolamine would impair memory performance on the ORT in rats. Numerous studies 
support the findings of the current study (Azmi, Norman, Spicer, & Bennett, 2006; Bertaina­
Anglade et aI., 2006; de Bruin & Pouzet, 2006; Dodart, Mathis, & Ungerer, 1997; Rutten, 
Prickaerts, & Blokland, 2006; Winters et aI., 2006). However, contrary to the current study, 
one study investigated the effects of Scopolamine on the ORT via direct infusion into the 
brain (Winters et aI., 2006). The current study utilized a methodology in which Scopolamine 
was injected via the intraperitoneal cavity. Various studies have found similar memory 
impairing effects of Scopolamine on the ORT via this route (Azmi et aI., 2006; Bertaina­
Anglade et aI., 2006; de Bruin & Pouzet, 2006, Rutten et aI., 2006). 
Numerous differences exist in the methodologies of research that supports 
Scopolamine-induced memory impairments on the ORT. Three major ways in which 
methodologies differ is in the dose of Scopolamine administered, the time it was 
administered prior to training, and the time delay used in the ORT. Scopolamine has been 
shown effective at inducing memory deficits at doses of 0.1 mg/kg (Bertaina-Anglade et aI., 
2006), 0.3 mg/kg (Bertaina-Anglade et aI., 2006; Dodart et aI., 1997),.0.63 mg/kg (de Bruin 
& Pouzet, 2006), 1 mg/kg (Bertaina-Anglade et aI., 2006, Dodart et aI., 1997), and 3 mglkg 
(Dodart et aI., 1997). Additionally, Winters et aI. (2006) effectively impaired memory 
performance on the ORT using a 10-mg/ml concentration of Scopolamine infused over 2 
minutes to each hemisphere of the brain for a total of 1 III per hemisphere. The current study 
utilized a dose of 1 mg/kg of Scopolamine to effectively impair memory on the ORT. It is 
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clear that a wide variety of Scopolamine doses are effective at inducing memory impairments 
on the aRT. 
The current study utilized a three-hour time delay in between training and testing on 
the aRT. One study has found similar results in regards to the decline ofmemory 
performance from Scopolamine after a three-hour delay between training and testing on the 
aRT (Dodart et aI., 1997). Other studies utilizing Scopolamine and the aRT have shown 
declined memory performance at delay intervals of one hour (Bertaina-Anglade et aI., 2006; 
de Bruin & Pouzet, 2006; Rutten et aI., 2006), four hours (de Bruin, et aI., 2006), up to 20 
hours (Winters et aI., 2006), and 24 hours (de Bruin et aI., 2006). In all cases, rats with 
Scopolamine-induced memory deficits showed significantly lower memory ability compared 
to rats without Scopolamine-induced deficits on the same time delay. Additionally, most 
studies were consistent with the current study in that Scopolamine was administered 30 
minutes prior to training on the aRT (Bertaina-Anglade et aI., 2006; de Bruin & Pouzet, 
2006; Rutten et aI., 2006). 
Social transmission offood preference task. No studies have investigated the effects 
of Scopolamine injected via the intraperitoneal cavity on memory performance in a STFP 
task. It was expected that Scopolamine would induce significant memory impairment during 
the testing phase of the STFP based on previous findings of Scopolamine on similar 
hippocampal-dependent memory tasks (Azmi et aI., 2006; Bertaina-Anglade et aI., 2006; de 
Bruin & Pouzet, 2006; Dodart et aI., 1997; Rutten et aI., 2006; Winters et aI., 2006). One 
study has utilized the STFP and found similar declined memory ability from Scopolamine 
administration as the current study; however, the methodology used is significantly different. 
Boix-Trelis et aI. (2007) infused Scopolamine directly into the prelimbic cortex, a component 
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of the medial prefrontal region. The drug was bilaterally injected at a dose of20 Ilg per site 
prior to training. Rats showed a severe impairment in performance on the STFP task 
measured in two retention sessions, both immediately and 24 hours after training (Boix­
Trelis et aI., 2007). In accordance with the findings of the current study, Scopolamine did 
significantly impair memory performance on the STFP task in both studies. 
In light ofthe results from Boix-Trelis et al. (2007) it is possible that some ofthe 
effects seen on memory performance in the current study may stem from blocking 
muscarinic cholinergic receptors in the prefrontal cortex. Since the current study injected 
Scopolamine via an intraperitoneal route, there is no way to verify exactly what muscarinic 
cholinergic receptors were being blocked in various areas of the brain. Various methods, 
such as chemical lesion or injection of a cholinergic muscarinic antagonist, of reducing 
cholinergic transmission in the prefrontal cortex and associated areas have been used to show 
decreased memory performance on working memory tasks and visual attention tasks 
(Chudasama, Dalley, Nathwani, Bougher, & Robbins, 2004). Similarly, the areas ofthe 
prefrontal cortex have been implicated in several functions necessary for relationalleaming 
such as behavioral flexibility (Dias, & Aggleton, 2000; Ragozzino, Detrick, & Kesner, 1999; 
Ragozzino, Kim, Hassert, Minniti, & Kiang, 2003), working memory .and attention (Dalley, 
Cardinal, & Robbins, 2004), and the organization and expression of adaptive behavior in 
novel circumstances (Gisquet-Verrier & Delatour, 2006). 
The current study attempted to impair cholinergic transmission in the hippocampus 
by blocking muscarinic cholinergic receptors in order to mimic acetylcholine deficiencies 
seen in AD. Results of the STFP, a hippocampal-dependent memory task, suggest that 
cholinergic receptors in the hippocampus were effectively blocked. However, previous 
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studies have shown declined memory perfonnance on the STFP from decreased 
acetylcholine transmission in the prefrontal cortex (Boix-Trelis et aI., 2007). Such findings 
indicate a possibility that some of the memory deficits observed in the current study could be 
due to similar effects. In such a case, the study would still be considered and effective model 
ofAlzheimer's disease since it is generally known that a decrease in ACh function exists in 
AD as well. 
It is still probable that much ofthe impainnent seen on the STFP task in the current 
study is due to muscarinic cholinergic blockages in the hippocampus and not the prefrontal 
cortex. Many studies have shown that the hippocampus and related areas are necessary for 
the delayed recall of the STFP task (Bunsey & Eichenbaum, 1995; Clark, Broadbent, Zola, & 
Squire, 2002; Countryman et aI., 2005; Roberts & Shapiro, 2002; Winocur, 1990; Winocur, 
McDonald, & Moscovitch, 2001). In line with this previous research, the current study 
utilized a five day delay in between training and testing on the STFP task. This lengthy 
delay, which highly implicates long-tenn memory and thus the hippocampus, is indicative of 
reduced cholinergic transmission in the hippocampus. 
The only other study to use Scopolamine-induced memory deficits on the STFP task 
used a shorter inter-trial delay than the current study. Boix-Trelis et al. (2007) utilized a 24 
hour delay to show the negative effects of Scopolamine on memory. Since the current study 
tested a delay of five days, it was expected that similar impaired memory perfonnance would 
be found. Many studies, using other memory tasks, have also utilized relatively short delay 
periods to test the effects of Scopolamine (Azmi et aI., 2006; 2006Beninger, Jhamandas, 
Boegman, & el-Defrawy, 1986; Bertaina-Anglade et aI., 2006; de Bruin & Pouzet, 2006; 
Dodart et aI., 1997; Rutten et aI., 2006; Winters et aI., 2006). The current study was unique 
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in the length of delay between trials but was still consistent with studies that utilized a four or 
five day inter-trial delays to test the effects of Scopolamine on memory performance in the 
Morris Water Maze task (Chalas & Conway, 1996; Herrera-Morales, Mar, Serrano, & 
Bermudez-Rattoni, 2007) 
Total Amount ofFood Consumed 
The results ofthe STFP task indicated that rats consumed significantly less food 
during testing periods ofall drug treatment compared to baseline conditions. The decreases 
in the total amount of food consumed may be attributed to two variables: the age ofthe rats at 
drug treatment conditions compared to baseline and possible stress caused by injections of 
Scopolamine, Guanfacine, and saline. The latter of the two hypotheses doesn't seem to be as 
credible as injections were only administered five minutes prior to training and 30 minutes 
after training. With the length of delay between training and testing periods being five days, 
it is not likely that the injections caused stress to be carried over into the testing and food 
consumption time period. However, this is still a plausible contributor to the decrease in 
amount of total food consumed. Additionally, it is not plausible that any side effects of 
Scopolamine or Guanfacine contributed to the decrease in the total amount of food consumed 
as over the five day delay, the majority of each ofthese drugs would have cleared the rats' 
system. 
The age ofthe rats seems to be the most likely cause ofthe decrease in total food 
consumed during drug treatment conditions. Baseline measures were conducted three 
months in advance of the drug treatment conditions while rats were still reaching full adult 
growth. It is plausible that rats ate more food during baseline testing due to the increase in 
amount of growth and body weight that was still occurring. Prior to drug treatment 
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conditions, rats had developed into adults and no longer required the amount of food they 
previously required to continue growing. This hypothesis is supported in two ways (see 
Figure 6): (l) rats still ate a substantial amount of food in the drug conditions and (2) the total 
amount of food consumed during each of the drug treatment conditions was relatively 
identical indicating that, perhaps, rats only needed to consume that much food in order to feel 
full. 
Ability ofGuanfacine to Reverse Scopolamine Impairments 
The current study investigated the ability of the norepinephrine agonist, Guanfacine, 
to reverse Scopolamine-induced memory impairments on the ORT and the STFP task. No 
previous study has tested the ability of Guanfacine to reverse Scopolamine-induced memory 
impairments on any memory tasks. Previous research has focused on acetylcholine agonists 
to reverse Scopolamine impairments on tasks such as the 8-arm radial arm maze task and the 
ORT. Studies have shown that Rolipram (Egawa, Mishima, Matsumoto, Iwasaki, Iwasaki, & 
Fujiwara, 1997; Rutten et aI., 2006), Pilocarpine (Levin & Torry, 1996; Riekkinen, Sirvio, 
Valjakka, Miettinen, & Riekkinen, 1991), Nebracetam (Iwasaki, Matsumoto, & Fukiwara, 
1992), and glucose, amphetamine, epinephrine, Physostigmine, and Oxotremorine (Stone, 
Walser, Gold, & Gold, 1991) all reverse the effects of Scopolamine on various memory 
tasks. 
No previous studies have investigated the ability of norepinephrine agonists to 
reverse the effects of Scopolamine. The current study is unique in that it investigated a 
specific alpha-2 receptor subtype adrenergic agonist, Guanfacine, in relation to its ability to 
reverse Scopolamine-induced memory deficits in the ORT and the STFP task. However, 
several studies have shown that norepinephrine agonists, specifically those of the alpha-2 
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subtype have improved memory perfonnance on a number of memory tasks (Amsten et aI., 
1988; Amsten & G01dman-Rakic, 1990; Amsten & Leslie, 1991; Amsten & Contant, 1992; 
Amsten & Cai, 1993; Jakala, et aI., 1999; Rama et aI., 1996; Sirvio et aI., 1991). 
One particular study is similar to the current study in that Guanfacine was 
investigated as a way to improve memory perfonnance on the STFP task in rats with a 
chemical lesion to the medial septal area. Opal & Countryman (2007) surgically gave a 
chemical lesion to the medial septal area in rats using 192 IgG-saporin. Following 
administration of the cholinergic neurotoxin, 192 IgG-saporin, subjects exhibited a 
significant decrease in memory fonnation when compared to baseline. Furthennore, 
following injection of Guanfacine into post-Iesioned rats, subjects displayed significant 
memory fonnation ability above chance levels. Results of this study were consistent with the 
current study regarding the effects of Guanfacine as a means to improve memory 
perfonnance on the STFP task. 
Effects ofGuanfacine Alone 
The results of the current study indicated that when Guanfacine was administered 
alone (to rats with no Scopolamine-induced memory deficits), there was a decrease in 
memory perfonnance on the ORT and the STFP compared to conditions in which 
Guanfacine was administered to rats with Scopolamine-induced memory deficits. Although 
the decreases observed in both tasks were not significant, the findings warrant explanation 
and discussion. 
One explanation for this decrease in memory perfonnance is that an excess of 
norepinephrine is detrimental when acetylcholine functioning is at nonnallevels. Perhaps 
the increase in norepinephrine above nonnallevels is only beneficial to memory perfonnance 
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when it is compensating for decreased acetylcholine functioning in the hippocampus. With 
both systems intact, excess norepinephrine may cause too much stimulation in the brain and 
lead to the inability of rats to focus their attention on behavioral tasks at hand. One study 
with healthy male participants supports this hypothesis (Mueller, Clark, Lam, Moore, 
Murphy, Richmond, et aI., 2005). Guanfacine was found to have no effects on executive and 
memory functions. Furthermore, negative effects on blood pressure and trend effects on 
backward digit span and reaction time indicated a mild impairment due to Guanfacine 
administration (Mueller et aI., 2005). 
Implications ofFindings: Guanfacine as an Alzheimer's Treatment 
The findings of the present study suggest that Guanfacine may be effective at 
improving memory impairments caused by decreased acetylcholine function as seen in 
Alzheimer's disease. The ability of this alpha-2 adrenergic agonist to reverse memory 
impairments caused by the muscarinic cholinergic antagonist, Scopolamine, establishes 
Guanfacine as a potentially effective treatment for memory impairments stemming from age­
associated cognitive impairments or Alzheimer's disease. Current AChE-I treatments for 
Alzheimer's disease are only effective for a short period of time. When the benefits of such 
treatments subside, no other alternative treatment for the associated impaired memory ability 
exists. Treatment with Guanfacine may be an option beyond that ofAChE-Is. 
One of the biggest steps that must be taken in order to establish Guanfacine and other 
noradrenergic drugs as potential treatment for memory impairment associated with 
Alzheimer's disease is to bridge the gap between animal research and human research. Many 
animal studies, including the current study, have shown that Guanfacine is able to improve 
previously lowered memory ability (Arnsten et aI., 1988; Arsten & Cai, 1993; Rama et aI., 
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1996; Sirvio et ai., 1991). For the most part, these studies did not intentionally impair 
memory, but rather used aged monkeys as test subjects. Few studies have administered 
Guanfacine to a human population, specifically Alzheimer's patients. The few studies that 
have generally conclude that Guanfacine was ineffective at improving memory impairments 
(Crook, Wilner, Rothwell, Winterling, & McEntee, 1992; McEntee, Crook, Jenkyn, Petrie, 
Larrabee, & Coffey, 1991). 
The current study may explain some of the conflicting findings between previous 
animal and human research with Guanfacine. Previous studies, which conclude that 
Guanfacine had no significant effect on learning and memory (McEntee et ai., 1991) and that 
noradrenergic intervention alone is unlikely to be effective in AD (Crook et ai., 1992), differ 
significantly in the way that Guanfacine was administered. These studies administered 
Guanfacine to patients meeting the criteria for age-associated memory impairment (McEntee 
et ai., 1991) and patients in the early stages of cognitive deterioration (Crook et ai., 1992). 
The diagnosis of these patients as mildly cognitively impaired likely means that acetylcholine 
levels are still mostly intact, or at least they haven't begun to deteriorate to the extent as seen 
in someone with a more advanced case of AD. This is supported by the results of one recent 
study, which shows that in early stages ofAlzheimer's disease ACh function is relatively 
normal (Ellis, Villemagne, Nathan, Mulligan, Gong, Chan, et ai., in press). 
The current study mimicked more advanced stages of AD in rats by blocking the 
majority of ACh transmission in the hippocampus. The improved results on impaired 
memory performance may be due, in part, to the lack of ACh functioning at the time of 
memory formation. In this respect, perhaps Guanfacine and noradrenergic treatment are only 
effective at reversing memory impairments when ACh functioning is severely impaired. 
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This fits with results of the current study. When Guanfacine was administered alone, 
memory ability on the ORT and STFP task tended to decrease compared to conditions in 
which Guanfacine was utilized to reverse Scopolamine-induced memory impairments. 
Results ofprevious studies testing Guanfacine on humans seem to be more aligned with this 
finding of the current study. Overall implications of this hypothesis suggest that Guanfacine 
may be beneficial at reducing memory impairment associated with advanced stages of AD. 
Limitations 
In order to improve future research it is beneficial to outline potential limitations of 
the current study. First, baseline levels ofmemory were taken approximately three months 
prior to any experimental testing. It is not likely that baseline memory levels would change 
substantially over such a period of time; however, it does remain a potential limitation. In 
future research it may be beneficial to have another baseline condition after all experimental 
manipulations are complete in order to serve as a confirmation for baseline memory levels. 
Secondly, there is no real AD in rats. The plaques and tangles associated with AD in humans 
never develop in rats. Rats serve as a beneficial animal model of AD in humans but AD 
cannot fully be represented in such a model. 
Another limitation of the current study is that there was no cellular confirmation of 
what brain structures Scopolamine affected. Results on each of the memory tasks suggest 
that most of the memory impairment would be due to the effects of Scopolamine blocking 
receptors in the HPC. Despite this, decreased ACh function caused by Scopolamine in other 
brain areas, such as the prefrontal cortex, could have accounted for some of the memory 
deficits in the current study. Even if this were the case, the model utilized in the current 
study would still serve as an effective one because of the known effects of ACh function in 
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both the HPC and prefrontal cortex in AD. However, effects in relation to other brain 
structures are not accounted for. A final limitation is that, despite the promising findings of 
memory improvement for patients with AD, cell death in the brain will continue to naturally 
occur. It is likely that such a treatment would only be effective for an additional year or two 
at most. 
Future Research 
Reversal of Scopolamine-induced memory impairment following the administration 
of Guanfacine, in the present experiment, contributes to the effectiveness of an animal model 
for AD in humans. Identifying the rat as a valid animal in which to manipulate treatment 
approaches to AD is one of the strengths of the present study. In the seemingly never-ending 
quest to uncover safe and effective pharmacological agents for AD, future research must 
utilize precise methodology. 
As previously mentioned, bridging the gap between animal studies, which currently 
test the ability of drugs such as Guanfacine to reverse or reduce memory impairment, and 
human studies is an important step for future research to consider. By testing these 
pharmacological agents on humans, more information can be ascertained regarding the 
benefits ofmemory ability in relation to AD. In line with previously discussed implications, 
it would be beneficial for future research to test the hypothesis that Guanfacine is effective at 
reducing memory impairments associated with severe and advanced cases of AD in humans. 
However, more research should be done with animal models prior to clinical trials in a 
human population. 
In order to fully test the ability of Guanfacine to reverse memory impairments, 
various hippocampal-dependent tasks should be utilized using varying inter-trial delays. 
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Research that shows the effects of the drug Guanfacine on other hippocampal-dependent 
memory tasks with varying inter-trial delays might further implicate the effectiveness of 
Guanfacine at reducing memory impairments as seen in AD. Furthermore, testing the 
administration of Guanfacine on varying levels ofACh functioning may give a clearer 
understanding of when in the stages ofAD Guanfacine may offer therapeutic support. 
Final Comments 
Since the onset of the "cholinergic hypothesis," considerable evidence has been 
obtained in support of impairment of the cholinergic system seen in Alzheimer's diseased 
patients (Bartus et aI., 1982). First, in the context of learning and memory tasks, 
predominant modulation of memory processing by acetylcholine has been shown to occur 
within the hippocampus (Dutar et aI., 1995). Numerous studies indicate that in human 
populations, AD is marked by a lack of cholinergic transmission within the hippocampal 
region (Bartus et aI., 1982; Rossor et aI., 1981). Recently, it is been shown that such decline 
in ACh function may only be significant in severe and advanced stages of AD (Ellis et aI., in 
press). The medial septal area, which exhibits neuronal projection to the hippocampus, has 
been implicated as the principal source of acetylcholine to the hippocampus (Vale-Martinez 
et aI., 2002). Consequently, lesions to the medial septum have produced widespread memory 
deficits via decreased availability of acetylcholine to the hippocampus (Potter et aI., 1999; 
Opal & Countryman, 2007). Additionally, Scopolamine has been shown to impair memory 
performance by blocking the hippocampal receptors available for ACh functioning (Rogers 
& Kesner, 2003). 
Clearly, the adrenergic and cholinergic systems are linked within the context of 
information acquisition and subsequent memory formation. One study by Kruglikov (1982) 
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indicated that impainnent did not exist on an avoidance memory task following 
administration of the cholinergic antagonist scopolamine. However, when Scopolamine was 
administered in conjunction with locus coeruleus lesions, drastic impainnent resulted. 
Another study by Harrell, Peagler, & Parsons (1990) reported that increases in impainnent 
were exhibited by rats on a radial maze apparatus following administration of the beta­
adrenergic antagonist Propranolol in conjunction with medial septum lesions. Application of 
Propranolol following lesion to the medial septum significantly worsened already decreased 
learning and memory perfonnance. Moreover, numerous observations have been made that 
stimulation of the alpha-2 adrenergic receptor within the locus coeruleus likely accounts for 
important on memory-related tasks (Arnsten et aI., 1988; Arnsten & Cai, 1993; Jakala et aI., 
1999). 
Findings in the current study support the link between cholinergic and noradrenergic 
neurotransmitter systems in relation to memory ability. It is not known by what mechanisms 
Guanfacine acts to improve memory ability. We suggest that Scopolamine works to prevent 
consolidation of infonnation attained during memory tasks. In this sense, infonnation may 
be encoded, but the longer, more involved process ofmemory consolidation may be blocked. 
Therefore, it is likely that administration ofGuanfacine helps to increase consolidation of any 
infonnation encoded and still retained from training on the memory tasks. This increased 
consolidation is thought to account for the improved memory ability, seen on the two 
memory tasks, in rats administered Scopolamine prior to training on the tasks. 
Conclusion 
The current study reports three meaningful findings: (l) Scopolamine significantly 
impairs memory perfonnance on two hippocampal-dependent memory tasks: the object 
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recognition task (ORT) and the social transmission of food preference task (STFP), (2) the 
administration of low dose of Guanfacine and a high dose of Guanfacine significantly 
improves memory impairments caused by Scopolamine on the ORT, and (3) a low-dose of 
Guanfacine (high dose not tested) significantly improves memory impairments caused by 
Scopolamine on the STFP task. Together, these findings significantly contribute to our 
knowledge ofmemory impairment and improvement, with regards to ACh and NE, and 
should be encouraging to those who study pharmacological treatment ofmemory deficits. 
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